We are searching data for your request:
Upon completion, a link will appear to access the found materials.
(YTB-393: dp. 237; 1. 100'; b. 25'; dr. 9'7"; s. 12 k.)
Nakarna (YTB-393) was laid down in September 1944 by Consolidated Shipbuilding Corp., Morris Heights, N.Y.
named 16 May, Iaunched 28 October, delivered 6 February 1945 and assigned duties in the 3d Naval District.
Her primary function was to support the Navy in the New York area. There she provided assistance in the vicinity of anchorages and piers for berthing and docking evolutions. She also provided towing services and waterfront fire protection, and served as an inner harbor patrol craft.
At the end of hostilities she was placed out of service and berthed with reserve units of the 16th Fleet at Green Cove Springs, Fla.
She was reactivated in August 1946 and assigned 6th Naval District duties in the immediate area of Charleston, S.C. Reclassified YTM-393 in February 1962, she continues to serve in support of the active forces of the Navy into 1970.
Abnormal Uterine Bleeding
Abnormal uterine bleeding is the medical term for abnormalities in the frequency, volume, duration, and regularity of the menstrual cycle. Abnormal uterine bleeding is classified using the acronym PALM-COEIN, with PALM representing the structural causes and COEIN indicating the non-structural causes. Etiologies include polyp (P), adenomyosis (A), leiomyoma (L), malignancy/hyperplasia (M), coagulopathy (C), ovulatory dysfunction (O) endometrial pathology including endometritis and atrophy (E), iatrogenic causes (I), and etiologies not otherwise classified (N). Diagnosis usually requires careful history-taking and examination, basic laboratory work, transvaginal ultrasound, and endometrial biopsy based on age and risk factors. Management depends on the underlying etiology, but often includes oral contraceptive pills, levonorgestrel-containing intrauterine devices, and surgery.
Sasakyan ng Isang Negosyante, Nakarnap!
*Echague, Isabela-* Sasampahan ng kasong Carnapping ang mga suspek na tumangay sa sasakyan ng isang Ginang na negosyante sa Brgy. Ipil, Echague, Isabela.
Kinilala ang biktima na si Rubilyn Pascual, 44 anyos, at residente ng Brgy. Salay, San Agustin, Isabela.
Batay sa imbestigasyon ng PNP Echague, natukoy ang pangunahing suspek na si Jose Villaseran kasama ng dalawa pang hindi pa nakikilalang mga suspek na kapwa residente ng Brgy. Ipil, Echague.
Tinangay ng mga nagpanggap na buyer ang Isuzu Truck na may plakang T-GDJ-804 matapos pumayag ang biktima na ibenta ang kaniyang sasakyan sa halagang limang daan at limampung libong iso (Php 550,000.00).
Kaugnay nito, hindi tumupad ang mga suspek na ibigay ang napag-usapang bayad sa anak ng biktima sa Brgy. San Fabian, Echague, Isabela hanggang sa hindi na makontak ng Ginang ang mga suspek.
Patuloy naman ang imbestigasyon ng mga awtoridad sa nasabing insidente upang madakip ang mga naturang suspek.
Nakarna YTB-393 - History
632 LAMBERTON ST TRENTON , NJ 08611 Get Directions
- Founded 2010
- Annual Revenue $180,000.00
- Employee Count 2
- Industries Travel Agencies
- Contacts SONYA FLOYSTROP
Ytb is located at 632 Lamberton St in Trenton and has been in the business of Travel Agencies since 2010.
Similar Businesses Nearby
- Sunday --
- Monday --
- Tuesday --
- Wednesday --
- Thursday --
- Friday --
- Saturday --
Menasha was assigned to the 5th Naval District, Norfolk, Virginia. She was reclassified YTM‑761 in September 1965. In the summer of 1966, Menasha was assigned to the 4th Naval District and the Philadelphia Naval Shipyard.
On 15 June 1986, Menasha was placed out of service and transferred to the Maritime Administration. Other sources indicate that Menasha was transferred to the National Defense Reserve Fleet in 1986, St. Lawrence SDC in 1989, sold as Menasha in 1995, and is now Escorte. 
Motor nga nakarnap, giturn over na
General Santos City—Anaa na sa kostudiya karon sa Pendatun Police Station General Santos ang motorsiklong biktima sa carnapping kaniadtong milabayng December 9 sa kaadlawon sa may area of responsibility sa Pendatun PNP Gensan.
Kahibaluan nga nabawi sa mga operatiba sa Glan Police Station ang Honda XLR kolor pula nga matud pa ginabaligya sa mga suspek nga giilang silang Teddy Utadora, 21 anyos, og Nelboy Awon nga taga Laguimit Glan Sarangani Province.
Apan padayon nga ginakwestiyon karon sa mga kabanay sa napatayng si Teddy Utadora ang pagpusil patay sa suspek sulod sa ilahang presento sa kapulisan sa Glan samtang ginaimbestigahan ang mga suspek.
Kahibaluan nga gihingusgan sa Glan PNP nga napugos na lamang og pagpusil si Police Chief Inspector Manuel Ryan Lim ngadto sa suspek human kining nangilog og pusil ni P02 Herbert Alinsugay samtang anaa sila sulod sa investigation section sa Glan PNP.
Matud pa sa mga kabanay sa napatay nga imposibling nangilog og armas ang suspek nga anaa naman sa ilahang kostudiya.
Sa pagkakaron misaad si Police Chief Inspector Niel Wadingan ang tigpamaba sa Sarangani PNP Command og patas nga imbestigasyon ngadto sa mga kabanay sa napatay.(Emir Bariquit)
Sleeve Gastrectomy Surgical Assistive Instrument for Accurate Remnant Stomach Volume
Elhajj, I. H., Dib, N., Antoun, S., and Al-Hajj, G. (August 4, 2010). "Sleeve Gastrectomy Surgical Assistive Instrument for Accurate Remnant Stomach Volume." ASME. J. Med. Devices. June 2010 4(2): 025001. https://doi.org/10.1115/1.4001520
Sleeve gastrectomy, which is based on reducing the size of the stomach, is one of the most successful bariatric surgeries and is yet to be standardized. One of the reasons is the lack of a method to obtain an accurate remnant stomach volume. The weight loss obtained postsurgery is highly correlated with the remnant stomach volume. Therefore, it is important to get consistently an accurate remnant stomach volume to be able to compare sleeve gastrectomy with other surgeries and in order to predict the weight loss. In addition, the measurement of the pyloric pressure is important for understanding the mechanism of weight loss and predicting complication postsurgery. A surgical assistive device for sleeve gastrectomy surgery is presented in this paper. The purpose of this instrument is to assist surgeons in obtaining an accurate remnant stomach volume and in measuring the pyloric pressure. The device consists of several inflatable compartments controllable by the surgeon. Prototype laboratory test results gave an accuracy of 96.7% and a repeatability of 97.6% for different desired volumes using air for compartment inflation, and an accuracy of 96.3% and a repeatability of 98.4% for different desired volumes using water for compartment inflation. The pressure measurement accuracies obtained are 96.8% using air and 99.7% using water. It is worth noting that these accuracies are expected to differ when the device is tested in vivo.
Tubersol is a prescription medicine used to treat the symptoms of Tuberculosis. Tubersol may be used alone or with other medications.
Tubersol belongs to a class of drugs called Diagnostics, Antimicrobials.
What are the possible side effects of Tubersol?
Tubersol may cause serious side effects including:
- difficulty breathing,
- burning in your eyes,
- swelling of your face or tongue, and
Get medical help right away, if you have any of the symptoms listed above.
The most common side effects of Tubersol include:
- injection site reactions (redness, ulceration of the skin, skin rash, pain, discomfort, or itching),
- shortness of breath,
- generalized rash, , and
Tell the doctor if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Tubersol. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Polysorbate 80 Stabilized Solution of Tuberculin Purified Protein Derivative for Tuberculin Testing in Humans
TUBERSOL®, Tuberculin Purified Protein Derivative (Mantoux) (PPD) (1) for intradermal tuberculin testing is prepared from a large Master Batch Connaught Tuberculin (CT68) (2) and is a cell-free purified protein fraction obtained from a human strain of Mycobacterium tuberculosis grown on a protein-free synthetic medium and inactivated. (2) The use of a standard preparation derived from a single batch (CT68) has been adopted in order to eliminate batch to batch variation by the same manufacturer. (2)
TUBERSOL is a clear, colorless liquid.
|Purified protein derivative of M. tuberculosis||5 TU per 0.1 mL|
|Phenol||0.22% to 0.35% w/v|
in sterile isotonic phosphate buffered saline.
Before release, each successive lot is tested for potency in comparison with the US Standard Tuberculin PPD-S. (3)
Independent studies conducted by the US Public Health Service in humans have determined the amount of CT68 in stabilized solution necessary (4) (5) (6) to produce bio-equivalency with Tuberculin PPD-S (in phosphate buffer without polysorbate 80) using 5 US units (TU) Tuberculin PPD-S as the standard.
1 Landi S. Preparation, purification, and stability of tuberculin. Appl Microbiol 196311:408-412.
2 Landi S, et al. Preparation and characterization of a large batch of tuberculin purified protein derivative (PPD-CT68). Ann Scalvo.198022:889-907.
3 US Code of Federal Regulations, Title 21, Part 610, Subpart C - Standard preparations and limits of potency.
4 Landi S, et al. Adsorption of tuberculin PPD to glass and plastic surfaces. Bull. WHO 196635:593-602.
5 Landi S, et al. Disparity of potency between stabilized and nonstabilized dilute tuberculin solutions. Am Rev Respir Dis 1971104:385-393.
6 Landi S, et al. Stability of dilute solutions of tuberculin purified protein derivative. Tubercle 197859:121-133.
TUBERSOL, Tuberculin Purified Protein Derivative (Mantoux), is indicated to aid diagnosis of tuberculosis infection (TB) in persons at increased risk of developing active disease.
The Centers for Disease Control and Prevention (CDC) have published guidelines regarding populations that would benefit from tuberculin skin testing (TST). Current recommendations can be accessed at: http://www.cdc.gov/tb/publications/factsheets/testing.htm.
Previous BCG vaccination is not a contraindication to tuberculin testing. The skin-test results of BCG vaccinated persons can be used to support or exclude the diagnosis of TB infection. However, an FDA-approved interferon gamma release assay is preferred over tuberculin skin test for persons 5 years of age and older who were previously vaccinated with BCG. (9)
DOSAGE AND ADMINISTRATION
Five (5) tuberculin units (TU) per test dose of 0.1 mL is the standard strength used for intradermal (Mantoux) testing.
Method Of Administration
TUBERSOL is indicated for intradermal injection only. Do not inject intravenously, intramuscularly, or subcutaneously. If subcutaneous injection occurs, the test cannot be interpreted.
Inspect for extraneous particulate matter and/or discoloration before use. If these conditions exist, do not administer the product.
Use a separate syringe and needle for each injection.
The following procedure is recommended for performing the Mantoux test:
- The preferred site of the test is the volar aspect of the forearm. Avoid areas on the skin that are red or swollen. Avoid visible veins.
- Clean the skin site with a suitable germicide and allow the site to dry prior to injection of the antigen.
- Administer the test dose (0.1 mL) of TUBERSOL with a 1 mL syringe calibrated in tenths and fitted with a short, one-quarter to one-half inch, 26 or 27 gauge needle.
- Wipe the stopper of the vial with a suitable germicide and allow to dry before needle insertion. Then insert the needle gently through the stopper and draw 0.1 mL of TUBERSOL into the syringe. Avoid injection of excess air with removal of each dose so as not to over pressurize the vial and possibly cause seepage at the puncture site.
- Insert the point of the needle into the most superficial layers of the skin with the needle bevel pointing upward and administer the dose by slow intradermal injection. If the intradermal injection is performed properly, a definite pale bleb will rise at the needle point, about 10 mm (3/8&rdquo) in diameter. This bleb will disperse within minutes. Do not dress the site.
- A drop of blood may appear at the administration site following injection. Blot the site lightly to remove the blood but avoid squeezing out the injected tuberculin test fluid.
In the event of an improperly performed injection (ie, no bleb formed), repeat the test immediately at another site, at least 2 inches from the first site and circle the second injection site as an indication that this is the site to be read.
Inform the patient of the need to return for the reading of the test by a trained health professional. Self-reading may be inaccurate and is strongly discouraged.
Interpretation Of The Test
The skin test should be read by a trained health professional 48 to 72 hours after administration of TUBERSOL. Skin test sensitivity is indicated by induration only redness should not be measured.
Measure the diameter of induration transversely to the long axis of the forearm and record the measurement in millimetres (including 0 mm). (8) The tip of a ballpoint pen, gently pushed at a 45° angle toward the site of injection, will stop at the edge of induration.
Also record presence and size (if present) of necrosis and edema, although these are not used in the interpretation of the test.
Tuberculin reactivity may indicate latent infection, prior infection and/or disease with M. tuberculosis and does not necessarily indicate the presence of active tuberculous disease. Persons showing positive tuberculin reactions should be considered positive by current public health guidelines and referred for further medical evaluation. (8) (10) The repeated testing of uninfected persons does not sensitize them to TUBERSOL. (7) (8) (10) (13)
The significance of induration measurements in diagnosing latent TB infection must be considered in terms of the patient's history and the risk of developing active TB disease as indicated in Table 1. (10)
Table 1: Criteria for tuberculin positivity, by risk group
|Reaction &ge 5 mm of Induration||Reaction &ge 10 mm of Induration||Reaction &ge 15 mm of Induration|
|HIV-positive persons |
Recent contacts of tuberculosis (TB) case patients
Fibrotic changes on chest radiograph consistent with prior TB
Patients with organ transplants and other immunosuppressed patients (receiving the equivalent of > 15 mg/d of prednisone for 1 month or more)*
|Recent immigrants (i.e., within the last 5 yrs) from high prevalence countries |
Injection drug users
Residents or employees&dagger of the following high-risk congregate settings: prisons and jails, nursing homes and other long-term facilities for the elderly, hospitals and other health care facilities, residential facilities for patients with acquired immunodeficiency syndrome (AIDS) and homeless shelters
Mycobacteriology laboratory personnel
Persons with the following clinical conditions that place them at high risk: silicosis, diabetes mellitus, chronic renal failure, some hematologic disorders (e.g., leukemias and lymphomas), other specific malignancies (e.g., carcinoma of the head or neck and lung), weight loss of &ge 10% of ideal body weight, gastrectomy and jejunoileal bypass
Children younger than 4 yrs of age or infants, children, and adolescents exposed to adults at high-risk
|Persons with no risk factors for TB|
|* Risk of TB in patients treated with corticosteroids increases with higher dose and longer duration. |
&daggerFor persons who are otherwise at low risk and are tested at the start of employment, a reaction of &ge 15 mm induration is considered positive.
A TST conversion is defined as an increase of &ge 10 mm of induration within a 2-year period, regardless of age. (10)
The possibility should be considered that the skin test sensitivity may also be due to a previous contact with atypical mycobacteria or previous BCG vaccination. (8) (10) (13)
An individual who does not show a positive reaction to 5 TU on the first test, but is suspected of being TB positive, may be retested with 5 TU. (See Booster Effect and Two-Step Testing) Any individual who does not show a positive reaction to an initial injection of 5 TU, or a second test with 5 TU may be considered as tuberculin negative.
False Positive Reactions
False positive tuberculin reactions can occur in individuals who have been infected with other mycobacteria, including vaccination with BCG. (8) (13) However, a diagnosis of M. tuberculosis infection and the use of preventive therapy should be considered for any BCG-vaccinated person who has a positive TST reaction, especially if the person has been, or is, at increased risk of acquiring TB infection. (See INDICATIONS AND USAGE) (15) (16)
Not all infected persons will have a delayed hypersensitivity reaction to a tuberculin test.
In those who are elderly or those who are being tested for the first time, reactions may develop slowly and may not peak until after 72 hours.
Since tuberculin sensitivity may take up to 8 weeks to develop following exposure to M. tuberculosis (See Mechanism of Action), persons who have a negative tuberculin test < 8 weeks following possible TB exposure should be retested &ge 8-10 weeks following the last known or suspected exposure. (17)
Altered Immune Status
Impaired or attenuated cell mediated immunity (CMI) can potentially cause a false negative tuberculin reaction. Many factors have been reported to cause a decreased ability to respond to the tuberculin test in the presence of tuberculous infection including viral infections (e.g., measles, mumps, chickenpox and HIV), live virus vaccinations (e.g., measles, mumps, rubella, oral polio and yellow fever), overwhelming tuberculosis, other bacterial infections, leukemia, sarcoidosis, fungal infections, metabolic derangements, low protein states, diseases affecting lymphoid organs, drugs (corticosteroids and many other immunosuppressive agents), and malignancy or stress. (8) (18) (19) A TST should be deferred for patients with major viral infections or live-virus vaccination in the past month. Persons with the common cold may be tuberculin tested.
Because TST results in HIV-infected individuals are less reliable as CD4 counts decline, screening should be completed as early as possible after HIV-infection occurs. (19)
Booster Effect And Two-Step Testing
If tuberculin testing will be conducted at regular intervals, for instance among health-care workers or prison workers, two-step testing should be performed as a baseline to avoid interpreting a booster effect as a tuberculin conversion. If the first test showed either no reaction or a small reaction, the second test should be performed one to four weeks later. Both tests should be read and recorded at 48 to 72 hours. Patients with a second tuberculin test (booster) response of &ge 10 mm should be considered to have experienced past TB infection. (15) (20)
Persons who do not boost when given repeat tests at one week, but whose tuberculin reactions change to positive after one year, should be considered to have newly acquired tuberculosis infection and managed accordingly. (7)
TUBERSOL, Tuberculin Purified Protein Derivative (Mantoux), bioequivalent to 5 US units (TU) PPD-S per test dose (0.1 mL) is supplied in:
10-test vial, 1 mL. NDC No. 49281-752-78 package of 1 vial, NDC No. 49281-752-21
50-test vial, 5 mL. NDC No. 49281-752-98 package of 1 vial, NDC No. 49281-752-22
The stopper of the vial for this product does not contain natural latex rubber.
Store at 2° to 8°C (35° to 46°F). (21) Do not freeze. Discard product if exposed to freezing.
Protect from light. Tuberculin PPD solutions can be adversely affected by exposure to light. The product should be stored in the dark except when doses are actually being withdrawn from the vial. (22)
A vial of TUBERSOL which has been entered and in use for 30 days should be discarded. (23)
Do not use after expiration date.
5 Landi S, et al. Disparity of potency between stabilized and nonstabilized dilute tuberculin solutions. Am Rev Respir Dis 1971104:385-393.
7 Menzies D. Interpretation of repeated tuberculin tests. Am J Respir Crit Care Med 1999159:15-21.
8 American Thoracic Society: Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000161:1376-1395.
9 CDC. Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection - United States, 2010. MMWR 2010 59 (RR-5):1-25.
10 CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 200049(RR-6):23-5.
11 Froeschle JE, et al. Immediate hypersensitivity reactions after use of tuberculin skin testing. Clin Infect Dis 200234:e12-13.
12 Brickman HF, et al. The timing of tuberculin tests in relation to immunization with live viral vaccines. Pediatrics: 197555:392-396.
13 Huebner RE, et al. Tuberculosis commentary: the tuberculin skin test. Clin Infect Dis 199317:968-75.
14 CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR 200251(RR-2):1-35.
15 CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR 200554(RR-17):1-141.
16 CDC. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR 1996 45(RR-4):8-9.
17 CDC. Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis: Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR 200554(RR-15):1-47.
18 Mori and Shiozawa. Suppression of tuberculin hypersensitivity caused by rubella infection. Am Rev Respir Dis 1985886-888.
19 CDC. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Recommendations from the CDC, the National Institutes of Health, and the HIV Medicine Association of Infectious Diseases Society of America. MMWR 200958(RR-4):1-207.
20 CDC. Prevention and control of tuberculosis in correctional and detention facilities: Recommendations from the CDC. MMWR 200655(RR-9):1-44.
21 Landi S, et al. Stability of dilute solution of tuberculin purified protein derivative at extreme temperatures. J Biol Stand 19819:195-199.
22 Landi S, et al. Effect of light on tuberculin purified protein derivative solutions. Am Rev Respir Dis 1975111:52-61.
23 Landi S, et al. Effect of oxidation on the stability of tuberculin purified protein derivative (PPD) In: International Symposium on Tuberculins and BCG Vaccine. Basel: International Association of Biological Standardization, 1983. Dev Biol Stand 198658:545-552.
Manufactured by: Sanofi Pasteur Limited, Toronto Ontario Canada. Distributed by: Sanofi Pasteur Inc., Swiftwater PA 18370 USA. Revised: March 2013
SASAKYANG NAKARNAP SA ILOILO, NAREKOBER SA KALIBO
Kalibo – Narekober at nasa kustodiya ngayon ng Highway Patrol Group ang isang pick up na sinasabing kinarnap sa Passi, Iloilo nitong nakaraang November 1 matapos abandonahin sa bahagi ng Tigayon, Kalibo bandang alas 5:00 kaninang umaga.
Police Staff Sergeant Bartolome of Provincial Highway Patrol Team-Aklan
Nabatid mula mismo kay Police Staff Sergeant Rayniel I. Bartolome ng Provincial Highway Patrol Team-Aklan, papunta na sana siya kaninang umaga sa Iloilo nang makita niya ang nasabing sasakyan na nakaparada nang wala sa ayos sa harap ng opisina ng LTO o Land Transportation Office.
Kaagad niya umano itong binalikan upang beripikahin nang maalaalang may napaulat na nawawalang pick up sa Iloilo.
Sa pag-uusisa, natuklasan umano ni Bartolome na iyon nga ang sasakyan dahilan upang makipag-ugnayan siya sa Passi City Highway Patrol Group.
Naghanap din umano muna sila ng mekaniko para makabitan muna ng battery para mapaandar, dahil nakakabit naman doon ang susi.
Samantala, nakikipag-ugnayan na rin sina Bartolome kay Barangay Captain Gil Morandante ng Barangay Tigayon upang matingnan kung nakunan ng CCTV ang lugar kung saan iniwan at tinanggal ang baterya ng sasakyan bago inabandona.
Samantala, nabatid na nakarehistro kay Bibiana Palomo ang sasakyan at ibinibenta narin sana, subalit hindi na umano ibinalik matapos i-test drive.